Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
RBC Capital analyst Frank Morgan maintains Humana (NYSE:HUM) with a Outperform and lowers the price target from $415 to $353.
UBS analyst Kevin Caliendo maintains Humana (NYSE:HUM) with a Neutral and lowers the price target from $334 to $326.
Cantor Fitzgerald analyst Sarah James maintains Humana (NYSE:HUM) with a Neutral and lowers the price target from $391 to $360.
Oppenheimer analyst Michael Wiederhorn maintains Humana (NYSE:HUM) with a Outperform and lowers the price target from $415 t...
Humana revises 2025 profit forecast due to disappointing Medicare Advantage reimbursement rates. Medical benefit ratio up to 88...
Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 3...
